FDA Approves Sanofi's Merilog As First Rapid-Acting Insulin Biosimilar Product For Diabetes
Sanofi's Merilog wins FDA approval as the first rapid-acting insulin biosimilar to Novolog, offering a new option for diabetes management.
pharmaphorum1d
Rival diabetes combinations Xultophy and Soliqua approved
Both products combine a long acting insulin with a GLP-1 analogue – Xultopy brings together Tresiba and Victoza, while Soliqua (formerly known as LixiLan) combines Lantus with Adlyxin (Lxyumia ...
pharmaphorum1d
Sanofi turns the tables on Lilly with biosimilar fast-acting insulin
Lantus sales are dropping fast because of the ... Novo Nordisk has responded to the threat from the cut-price fast and long-acting insulins with newer insulins that aim to improve on the ...
Medscape17y
Nocturnal Hypoglycemia: Answering the Challenge With Long-acting Insulin Analogs
Trials including commercially available formulations of insulin detemir or insulin glargine were compared with NPH. Pertinent English-language clinical trials published between 2000 and 2006 were ...
Medscape2y
Safety of Insulin Glargine Use in Pregnancy
New insulin analogues such as the long-acting analogue insulin glargine may represent beneficial treatment options in pregnancy by ensuring that patients achieve excellent glycemic control without ...
Nature5y
Diabetic ketoacidosis, long-acting insulin analogs and pediatric type 1 diabetes mellitus
Use of the long-acting insulin analogs glargine and detemir does not reduce the risk of diabetic ketoacidosis in children and adolescents with type 1 diabetes mellitus (T1DM), compared with the ...